Study summary
Targeted pills shrank most BRAF-mutated anaplastic thyroid cancers
68%had their tumors shrink on BRAF and MEK pills
What was tested
A pooled look at studies of BRAF and MEK inhibitor pills, such as dabrafenib with trametinib, in anaplastic thyroid cancer with the BRAF V600E gene change, found in about 45% of these tumors.
What they found
- Tumors shrank in about 68% of people.
- About 65% were alive at 1 year and 52% at 2 years.
- Results were better when the pills were given before surgery.
- No new or unexpected side effects were found.
What it means
For a cancer that was once almost always fatal within months, this changed outlook for people with the BRAF change. Testing for it quickly is essential.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.